Fig. 3From: Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody a Pharmacokinetics of BAN2401, with mean serum concentration of BAN2401 in SAD cohorts. b Mean serum concentration of BAN2401 after the last dose in MAD cohorts of 0.3 – 3 mg/kg every 28 days (4 doses), or 10 mg/kg biweekly (7 doses). SAD single ascending dose, MAD multiple ascending doseBack to article page